Information for activists, patients, health workers & researchers working to end tuberculosis
Website of the Global Tuberculosis Community Advisory Board
By Infectex, Ltd. Published: Feb. 21, 2014, 5:30 p.m.· Tags: Drug-resistant TB
Russian biotech company Infectex, Ltd., recently announced that it has entered into license agreement with Qurient, Ltd., of Korea for the exclusive rights to develop and market Qurient’s Q203 treatment against Tuberculosis.
Read More →
Page 1 of 1 · Total posts: 1
